SCHEMBL7684976

SCHEMBL7684976

CCC(C(C)=O)(C(=O)O)C(=O)O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.35
FFAR3 O14843 3/20 0.35
TDP1 Q9NUW8 2/20 0.35
MEN1 O00255 1/20 0.34
CYP1A2 P05177 1/20 0.34
THRB P10828 1/20 0.34
KMT2A Q03164 1/20 0.34
TSHR P16473 3/20 0.33
THPO P40225 1/20 0.33
LCK P06239 1/20 0.33
FYN P06241 1/20 0.33
CYP2D6 P10635 1/20 0.32
CYP2C19 P33261 1/20 0.32
HIF1A Q16665 1/20 0.32
CES1 P23141 1/20 0.31
HDAC3 O15379 1/20 0.30
HDAC1 Q13547 1/20 0.30
HDAC2 Q92769 1/20 0.30
HDAC8 Q9BY41 1/20 0.30
GRM2 Q14416 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10345101 0.94 ALDH1A1 (0.35) ALDH1A1FFAR3TDP1MEN1CYP1A2
SCHEMBL27727275 0.92 ALDH1A1 (0.33) ALDH1A1FFAR3TDP1MEN1CYP1A2
SCHEMBL27570687 0.92 ALDH1A1 (0.33) ALDH1A1FFAR3TDP1MEN1CYP1A2
SCHEMBL27589221 0.92 ALDH1A1 (0.33) ALDH1A1FFAR3TDP1MEN1CYP1A2
SCHEMBL27598364 0.85 TDP1 (0.35) ALDH1A1FFAR3TDP1MEN1CYP1A2
SCHEMBL115741 0.84 FFAR3 (0.41) ALDH1A1FFAR3TDP1MEN1CYP1A2
SCHEMBL6910126 0.84 ALDH1A1 (0.41) ALDH1A1FFAR3TDP1TSHRTHPO
SCHEMBL27679980 0.83 KDM4E (0.38) ALDH1A1TDP1
SCHEMBL28419811 0.81 FFAR3 (0.39) ALDH1A1FFAR3TDP1MEN1CYP1A2
Water SCHEMBL5129171 0.81 FFAR3 (0.39) ALDH1A1FFAR3TDP1MEN1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6455703-B2 ADMINISTERING EFFECTIVE AMOUNT OF 1,3,6-TRIHYDRO-6-AZA-3-OXAPENTALEN-2-ONE DERIVATIVE TO THE PATIENT FOR INDUCING OR PROMOTING APOPTOSIS AND FOR ARRESTING UNCONTROLLED NEOPLASTIC CELL PROLIFERATION CELL PATHWAYS, INC. 2002-09-24 US disclosed
US-20010051651-A1 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia OSI PHARMACEUTICALS, INC. 2001-12-13 US disclosed
US-6160003-A 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia CELL PATHWAYS, INC. (US) 2000-12-12 US disclosed
US-5939417-A 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia CELL PATHWAYS INC (US) 1999-08-17 US disclosed
CN-86105901-A Agricultural chemical compound 1987-03-11 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010051651-A1 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia MALT1, VHL, CDKN1A ALDH1A1 208/4885FFAR3 3710/4885TDP1 925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.